Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Carmat SA Obtains Approval to Carry Out Human Implants of Its Bioprosthetic Artificial Heart


Monday, 23 Sep 2013 06:30pm EDT 

Carmat SA announced that the Agence Nationale de Securite du Medicament et des produits de sante (ANSM, French health authority) has authorized the Company to carry out the human implants of its bioprosthetic artificial heart on four patients in three approved French hospitals. 

Latest Developments for Carmat SA

Company Quote

69.25
-0.45 -0.65%
30 Jan 2015